EUCTR2013-000366-11-SK进行中（未招募）1 期
A Randomised Active-Controlled Double-Blind and Open Label Extension Study to Evaluate the Efficacy, Long-term Safety and Tolerability of TP05 3.2 g/day for the Treatment of Active Ulcerative Colitis (UC)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Male or non-pregnant, non-lactating females, 18 years of age or older. Females of child bearing potential must have a negative serum pregnancy test prior to randomisation, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of one year since the last menstrual period]).
- •(2) Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.
- •(3) Active UC defined by:
- •a. Mayo score of > 5
- •b. Sigmoidoscopy component score = 2 confirmed by central review and
- •c. Rectal bleeding component score = 1
- •(4) Ability of the subject to participate fully in all aspects of this clinical trial.
- •(5) Written informed consent must be obtained and documented.
- •(1) Attendance at the Week 8 visit and completion of disease activity assessments prior to enrolment in OLE at Week 12 (responders or remitters) or Week 8 (non-responders).
- •(2) At least 75% compliance with study medication in the induction phase.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 752
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 48
排除标准
- •(1) Severe UC defined by the following criteria:
- •= 6 bloody stools daily with one or more of the following:
- •a. oral temperature > 37.8°C or > 100.0°F
- •b. pulse > 90 beats/min
- •c. haemoglobin < 10 g/dL
- •(2) Treatment with mesalamine at a dose of > 2.4 g/day within 4 weeks prior to randomisation.
- •(3) Treatment with systemic or rectal steroids within 4 weeks prior to randomisation.
- •(4) Treatment with immunosuppressants within 6 weeks prior to randomisation.
- •(5) Treatment with infliximab or other biologics within 3 months prior to randomisation.
- •(6) Treatment with systemic antibiotics for UC within 7 days prior to randomisation.
- •(7) Treatment with probiotics within 7 days prior to randomisation
- •(8) Treatment with anti-diarrhoeals within 7 days prior to randomisation
- •(9) Treatment with nicotine patch within 7 days prior to randomisation.
- •(10) Received any investigational drug within 30 days prior to randomisation.
- •(11) History of colectomy or partial colectomy.
- •(12) History of definite dysplasia in colonic biopsies.
- •(13) Crohn’s disease.
- •(14) Immediate or significant risk of toxic megacolon.
- •(15) Known bleeding disorders.
- •(16) Hypersensitivity to salicylates, aspirin, sulfasalazine or 5-ASA.
- •(17) Serum creatinine > 1.5 times the upper limit of the normal range.
- •(18) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin or alkaline phosphatase > 2 times the upper limit of the normal range.
- •(19) Serious underlying disease other than UC which in the opinion of the investigator may interfere with the subject’s ability to fully participate in the study.
- •(20) History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject’s ability to comply with the study procedures.
- •(21) Stools positive for Clostridium difficile toxin.
- •(22) Pregnant or lactating women.
- •(23) Prior enrolment in the study.
- •(1) Withdrawal from the induction phase prior to the Week 8 visit.
研究者
相似试验
进行中（未招募）
1 期
Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.lcerative colitisMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-000366-11-PLTillotts Pharma AG800
进行中（未招募）
1 期
Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.lcerative colitisMedDRA version: 18.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-000366-11-ROTillotts Pharma AG817
进行中（未招募）
1 期
Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.lcerative colitisMedDRA version: 18.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-000366-11-BGTillotts Pharma AG800
进行中（未招募）
1 期
Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.lcerative colitisMedDRA version: 17.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-000366-11-LTTillotts Pharma AG800
进行中（未招募）
1 期
Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.lcerative colitisMedDRA version: 17.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2013-000366-11-FITillotts Pharma AG800